Atrium Therapeutics, Inc.
- Last sale
- Nov 2, 2026 · +3.26%
- Market cap
- $184.65M
- 21.57M shares
- Filings
- 61
Q3 2026
—Q3 2026
—Q3 2026
—Q3 2026derived
—Q3 2026
—Q3 2026
- $184.65M
- —
- —
- 0.9×
- —
- —
FY2026 figures · derived
Price
Nov 2, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
No annual history for this metric yet.
| Period | Ended | Value | Kind | Source trail |
|---|
Pharmaceutical preparations
Atrium Therapeutics, Inc. is the 254th largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
RNACCartesian Therapeutics, Inc.$2.8M92.8%4,658.6%$194.3MBBOTBridgeBio Oncology Therapeutics, Inc.———$191.4MPYXSPyxis Oncology, Inc.$13.9M14.2%574.5%$189.0M
RNAAtrium Therapeutics, Inc. (this company)———$184.7M
WHWKWhitehawk Therapeutics, Inc.$7.1M72.5%288.3%$181.7MADCTADC Therapeutics SA$81.4M14.9%175.3%$178.8MNATRNatures Sunshine Products Inc$480.1M5.7%4.1%$178.3MORMPOramed Pharmaceuticals Inc.$2.0M—3,202.5%$175.2MGTBPGT Biopharma, Inc.———$174.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Atrium Therapeutics, Inc. · CIK 2093101 · Engraved from SEC EDGAR